Multifunctional, Nanoparticle-Based, Therapies for the Treatment of Periodontal D

Information

  • Research Project
  • 8127501
  • ApplicationId
    8127501
  • Core Project Number
    R43DE021290
  • Full Project Number
    1R43DE021290-01A1
  • Serial Number
    21290
  • FOA Number
    PA-10-050
  • Sub Project Id
  • Project Start Date
    4/1/2011 - 13 years ago
  • Project End Date
    3/31/2012 - 12 years ago
  • Program Officer Name
    LUMELSKY, NADYA L.
  • Budget Start Date
    4/1/2011 - 13 years ago
  • Budget End Date
    3/31/2012 - 12 years ago
  • Fiscal Year
    2011
  • Support Year
    1
  • Suffix
    A1
  • Award Notice Date
    2/25/2011 - 13 years ago

Multifunctional, Nanoparticle-Based, Therapies for the Treatment of Periodontal D

DESCRIPTION (provided by applicant): The objective of this Phase I SBIR proposal is to provide improved therapies for the treatment of periodontal disease. Periodontal Disease is a chronic infectious disease of the oral cavity that effects about 35 % of the adult population in the United States, or slightly more than 40 million people.1-12 In severe cases, periodontal disease can lead to a failure of the underlying bone structure and necessitate surgical extraction and replacement of the teeth. In the U.S alone, the cost of treating periodontal disease was estimated at $19 billion dollars annually in 19984. The innovation proposed is to produce multifunctional, surface-modified nanoparticle carriers that are designed to bind robustly to hard tissue surfaces and bacterial biofilms, and may deliver multiple therapeutic payloads. Because the nanoparticles may bind to tissue surfaces and to bacterial biofilms, the carriers may have substantive (long lasting) therapeutic effects within the periodontal pocket, a major shortcoming of current therapies. The ability to localize and chemically attach the drug-carrier within the periodontium is a major advantage of the proposed innovation, since conventional therapies all suffer from the fact that the drugs are rapidly cleared by the turnover of gingival crevicular fluid (saliva).7 The proposed innovation, if successful, will be capable of managing multiple therapeutic chemistries and deliver them to the periodontal pocket and gingival tissues at efficacious levels over an extended period of time, without repeated intervention from a clinician. PUBLIC HEALTH RELEVANCE: Periodontal Disease is a chronic infectious disease of the oral cavity that effects about 35 % of the adult population in the United States, or slightly more than 40 million people. This SBIR seeks to overcome the shortcomings of current therapies for periodontal disease, and to provide a therapy that is capable of managing multiple therapeutic chemistries, delivering them to disease sites over an extended period of time, without the repeated intervention from a clinician.

IC Name
NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH
  • Activity
    R43
  • Administering IC
    DE
  • Application Type
    1
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    149844
  • Sub Project Total Cost
  • ARRA Funded
    False
  • CFDA Code
    121
  • Ed Inst. Type
  • Funding ICs
    NIDCR:149844\
  • Funding Mechanism
    SBIR-STTR
  • Study Section
    MTE
  • Study Section Name
    Musculoskeletal Tissue Engineering Study Section
  • Organization Name
    TRANSPARENT MATERIALS, LLC
  • Organization Department
  • Organization DUNS
    828749759
  • Organization City
    ROCHESTER
  • Organization State
    NY
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    146500001
  • Organization District
    UNITED STATES